NeuroOne Expected to Join Russell Microcap Index, Boosting Visibility Among Investors

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that it is expected to join the Russell Microcap Index as part of the first semi-annual 2026 Russell indexes reconstitution. The company appears on preliminary index additions lists published by FTSE Russell on May 22, May 29, and June 5, 2026. The newly reconstituted indexes will take effect after the U.S. market close on Friday, June 26, 2026.

Dave Rosa, Chief Executive Officer of NeuroOne, expressed optimism about the development. ‘We are pleased that NeuroOne is expected to be added to the Russell Microcap Index. We believe our inclusion reflects the commercial momentum we have built across our portfolio of FDA-cleared electrode and ablation technologies, and the increasing recognition of NeuroOne within the investment community,’ Rosa said. ‘We expect membership in the index to expand our visibility among institutional investors and broaden our shareholder base as we continue our mission of transforming the treatment of neurological disorders.’

FTSE Russell previously announced that the reconstitution of the Russell US Indexes is changing from an annual to a semi-annual schedule beginning in 2026. The Russell Microcap Index is designed to track the performance of the smallest 1,000 companies in the Russell 2000 Index, making it a key benchmark for micro-cap investors. Inclusion in the index typically triggers automatic buying by index funds and can increase a company’s exposure to a broader range of investors.

NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These solutions aim to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. More information is available at nmtc1.com.

The announcement underscores NeuroOne’s growing commercial traction and its potential to attract more institutional investment. For a company focused on neurological disorders, inclusion in a widely followed index could provide the capital needed to advance its pipeline and expand market reach. However, the company cautioned that forward-looking statements involve risks, including uncertainties about market acceptance, regulatory approvals, and the ability to raise additional funds. Detailed risk factors are available in NeuroOne’s filings with the Securities and Exchange Commission.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is NeuroOne Expected to Join Russell Microcap Index, Boosting Visibility Among Investors.

The post NeuroOne Expected to Join Russell Microcap Index, Boosting Visibility Among Investors appeared first on citybuzz.